Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
XIGDUO® XR
(dapagliflozin and metformin HCl) Extended-Release
Tablets
WARNING
LACTIC ACIDOSIS
XIGDUO XR (dapagliflozin and metformin HCl) extended-release tablets contain two oral antihyperglycemic medications used in the management of type 2 diabetes: dapagliflozin and metformin hydrochloride.
Dapagliflozin is described chemically as D-glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, (1S)-, compounded with (2S)-1,2-propanediol, hydrate (1:1:1). The empirical formula is C21H25ClO6•C3H8O2•H2O and the formula weight is 502.98. The structural formula is:
 |
Metformin hydrochloride (N,N-dimethylimidodicarbonimidic diamide hydrochloride) is a white to off-white crystalline compound with a molecular formula of C4H11N5•HCl and a molecular weight of 165.63. Metformin hydrochloride is freely soluble in water, slightly soluble in alcohol, and is practically insoluble in acetone, ether, and chloroform. The pKa of metformin is 12.4. The pH of a 1% aqueous solution of metformin hydrochloride is 6.68. The structural formula is:
 |
XIGDUO XR is available for oral administration as tablets containing the equivalent of 5 mg dapagliflozin as dapagliflozin propanediol and 500 mg metformin hydrochloride (XIGDUO XR 5 mg/500 mg), the equivalent of 5 mg dapagliflozin as dapagliflozin propanediol and 1000 mg metformin hydrochloride (XIGDUO XR 5 mg/1000 mg), the equivalent of 10 mg dapagliflozin as dapagliflozin propanediol and 500 mg metformin hydrochloride (XIGDUO XR 10 mg/500 mg), or the equivalent of 10 mg dapagliflozin as dapagliflozin propanediol and 1000 mg metformin hydrochloride (XIGDUO XR 10 mg/1000 mg).
Each film-coated tablet of XIGDUO XR contains the following inactive ingredients: microcrystalline cellulose, lactose anhydrous, crospovidone, silicon dioxide, magnesium stearate, carboxymethylcellulose sodium, and hypromellose 2208. The 5 mg/500 mg and 5 mg/1000 mg strength tablets of XIGDUO XR also contain hypromellose 2910.
The film coatings contain the following inactive ingredients: polyvinyl alcohol, titanium dioxide, polyethylene glycol, and talc. Additionally, the film coating for the XIGDUO XR 5 mg/500 mg tablets contains FD&C Yellow No. 6/Sunset Yellow FCF aluminum lake and the film coating for the XIGDUO XR 5 mg/1000 mg, 10 mg/500 mg, and 10 mg/1000 mg tablets contains iron oxides.
XIGDUO XR (dapagliflozin and metformin HCl extended-release) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate [see Clinical Studies].
XIGDUO XR is not recommended for patients with type 1 diabetes mellitus or diabetic ketoacidosis.
Assess renal function before initiating XIGDUO XR therapy and periodically thereafter.
XIGDUO XR is contraindicated in patients with an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73 m² [see CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS, and Use in Specific Populations].
No dose adjustment for XIGDUO XR is needed in patients with mild renal impairment (eGFR of 60 mL/min/1.73 m² or greater).
Discontinue XIGDUO XR at the time of, or prior to, an iodinated contrast imaging procedure in patients with a history of liver disease, alcoholism or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Reevaluate eGFR 48 hours after the imaging procedure; restart XIGDUO XR if renal function is stable [see WARNINGS AND PRECAUTIONS].
XIGDUO XR is a combination of dapagliflozin and metformin HCl extended-release. XIGDUO XR tablets are available in the following dosage forms and strengths:
XIGDUO® XR (dapagliflozin and metformin HCl extended-release) tablets have markings on one side, are plain on the reverse side, and are available in the strengths and packages listed in Table 15.
Table 15: XIGDUO XR Tablet Presentations
| Tablet Strength | Film-Coated Tablet Color/Shape | Tablet Markings | Pack Size | NDC Code |
| 5/500 mg | orange, biconvex, capsule-shaped | “1070” and “5/500” debossed on one side and plain on the reverse side. | Bottle of 30 | 0310-6250-30 |
| Bottle of 500 | 0310-6250-50 | |||
| 5/1000 mg | pink to dark pink, biconvex, oval-shaped | “1071” and “5/1000” debossed on one side and plain on the reverse side. | Bottle of 30 | 0310-6260-30 |
| Bottle of 60 | 0310-6260-60 | |||
| Bottle of 90 | 0310-6260-90 | |||
| Bottle of 400 | 0310-6260-40 | |||
| 10/500 mg | pink, biconvex, capsule-shaped | “1072” and “10/500” debossed on one side and plain on the reverse side. | Bottle of 30 | 0310-6270-30 |
| Bottle of 500 | 0310-6270-50 | |||
| 10/1000 mg | yellow to dark yellow, biconvex, oval-shaped | “1073” and “10/1000” debossed on one side and plain on the reverse side | Bottle of 30 | 0310-6280-30 |
| Bottle of 90 | 0310-6280-90 | |||
| Bottle of 400 | 0310-6280-40 |
Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].
Distributed by: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850. Revised: Mar 2017
The following important adverse reactions are described below and elsewhere in the labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Data from a prespecified pool of patients from 8 short-term, placebo-controlled studies of dapagliflozin coadministered with metformin immediate-or extended-release was used to evaluate safety. This pool included several add-on studies (metformin alone and in combination with a dipeptidyl peptidase-4 [DPP4] inhibitor and metformin, or insulin and metformin, 2 initial combination with metformin studies, and 2 studies of patients with cardiovascular disease [CVD] and type 2 diabetes who received their usual treatment [with metformin as background therapy]). For studies that included background therapy with and without metformin, only patients who received metformin were included in the 8-study placebo-controlled pool. Across these 8 studies 983 patients were treated once daily with dapagliflozin 10 mg and metformin and 1185 were treated with placebo and metformin. These 8 studies provide a mean duration of exposure of 23 weeks. The mean age of the population was 57 years and 2% were older than 75 years. Fifty-four percent (54%) of the population was male; 88% White, 6% Asian, and 3% Black or African American. At baseline, the population had diabetes for an average of 8 years, mean hemoglobin A1c (HbA1c) was 8.4%, and renal function was normal or mildly impaired in 90% of patients and moderately impaired in 10% of patients.
The overall incidence of adverse events for the 8-study, short-term, placebo-controlled pool in patients treated with dapagliflozin 10 mg and metformin was 60.3% compared to 58.2% for the placebo and metformin group. Discontinuation of therapy due to adverse events in patients who received dapagliflozin 10 mg and metformin was 4% compared to 3.3% for the placebo and metformin group. The most commonly reported events leading to discontinuation and reported in at least 3 patients treated with dapagliflozin 10 mg and metformin were renal impairment (0.7%), increased blood creatinine (0.2%), decreased renal creatinine clearance (0.2%), and urinary tract infection (0.2%).
Table 1 shows common adverse reactions associated with the use of dapagliflozin and metformin. These adverse reactions were not present at baseline, occurred more commonly on dapagliflozin and metformin than on placebo, and occurred in at least 2% of patients treated with either dapagliflozin 5 mg or dapagliflozin 10 mg.
Table 1: Adverse Reactions in Placebo-Controlled
Studies Reported in ≥ 2% of Patients Treated with Dapagliflozin and
Metformin
| Adverse Reaction | % of Patients | ||
| Pool of 8 Placebo-Controlled Studies | |||
| Placebo and Metformin N=1185 |
Dapagliflozin 5 mg and Metformin N=410 |
Dapagliflozin 10 mg and Metformin N=983 |
|
| Female genital mycotic infections1 | 1.5 | 9.4 | 9.3 |
| Nasopharyngitis | 5.9 | 6.3 | 5.2 |
| Urinary tract infections2 | 3.6 | 6.1 | 5.5 |
| Diarrhea | 5.6 | 5.9 | 4.2 |
| Headache | 2.8 | 5.4 | 3.3 |
| Male genital mycotic infections3 | 0 | 4.3 | 3.6 |
| Influenza | 2.4 | 4.1 | 2.6 |
| Nausea | 2.0 | 3.9 | 2.6 |
| Back pain | 3.2 | 3.4 | 2.5 |
| Dizziness | 2.2 | 3.2 | 1.8 |
| Cough | 1.9 | 3.2 | 1.4 |
| Constipation | 1.6 | 2.9 | 1.9 |
| Dyslipidemia | 1.4 | 2.7 | 1.5 |
| Pharyngitis | 1.1 | 2.7 | 1.5 |
| Increased urination4 | 1.4 | 2.4 | 2.6 |
| Discomfort with urination | 1.1 | 2.2 | 1.6 |
| 1Genital mycotic infections include the
following adverse reactions, listed in order of frequency reported for females:
vulvovaginal mycotic infection, vaginal infection, genital infection,
vulvovaginitis, fungal genital infection, vulvovaginal candidiasis, vulval
abscess, genital candidiasis, and vaginitis bacterial. (N for females: Placebo
and metformin=534, dapagliflozin 5 mg and metformin=223, dapagliflozin 10 mg
and metformin=430). 2Urinary tract infections include the following adverse reactions, listed in order of frequency reported: urinary tract infection, cystitis, pyelonephritis, urethritis, and prostatitis. 3Genital mycotic infections include the following adverse reactions, listed in order of frequency reported for males: balanitis, fungal genital infection, balanitis candida, genital candidiasis, genital infection, posthitis, balanoposthitis. (N for males: Placebo and metformin=651, dapagliflozin 5 mg and metformin=187, dapagliflozin 10 mg and metformin=553). 4Increased urination includes the following adverse reactions, listed in order of frequency reported: pollakiuria, polyuria, and urine output increased. |
|||
In placebo-controlled monotherapy trials of metformin extended-release, diarrhea and nausea/vomiting were reported in > 5% of metformin-treated patients and more commonly than in placebo-treated patients (9.6% versus 2.6% for diarrhea and 6.5% versus 1.5% for nausea/vomiting). Diarrhea led to discontinuation of study medication in 0.6% of the patients treated with metformin extended-release.
The data in Table 2 are derived from 12 placebo-controlled studies ranging from 12 to 24 weeks. In 4 studies dapagliflozin was used as monotherapy, and in 8 studies dapagliflozin was used as add-on to background antidiabetic therapy or as combination therapy with metformin [see Clinical Studies].
These data reflect exposure of 2338 patients to dapagliflozin with a mean exposure duration of 21 weeks. Patients received placebo (N=1393), dapagliflozin 5 mg (N=1145), or dapagliflozin 10 mg (N=1193) once daily. The mean age of the population was 55 years and 2% were older than 75 years of age. Fifty percent (50%) of the population were male; 81% were White, 14% were Asian, and 3% were Black or African American. At baseline, the population had diabetes for an average of 6 years, had a mean HbA1c of 8.3%, and 21% had established microvascular complications of diabetes. Baseline renal function was normal or mildly impaired in 92% of patients and moderately impaired in 8% of patients (mean eGFR 86 mL/min/1.73 m²).
Table 2 shows common adverse reactions associated with the use of dapagliflozin. These adverse reactions were not present at baseline, occurred more commonly on dapagliflozin than on placebo, and occurred in at least 2% of patients treated with either dapagliflozin 5 mg or dapagliflozin 10 mg.
Table 2: Adverse Reactions
in Placebo-Controlled Studies Reported in ≥ 2% of Patients Treated with
Dapagliflozin
| Adverse Reaction | % of Patients | ||
| Pool of 12 Placebo-Controlled Studies | |||
| Placebo N=1393 |
Dapagliflozin 5 mg N=1145 |
Dapagliflozin 10 mg N=1193 |
|
| Female genital mycotic infections1 | 1.5 | 8.4 | 6.9 |
| Nasopharyngitis | 6.2 | 6.6 | 6.3 |
| Urinary tract infections2 | 3.7 | 5.7 | 4.3 |
| Back pain | 3.2 | 3.1 | 4.2 |
| Increased urination3 | 1.7 | 2.9 | 3.8 |
| Male genital mycotic infections4 | 0.3 | 2.8 | 2.7 |
| Nausea | 2.4 | 2.8 | 2.5 |
| Influenza | 2.3 | 2.7 | 2.3 |
| Dyslipidemia | 1.5 | 2.1 | 2.5 |
| Constipation | 1.5 | 2.2 | 1.9 |
| Discomfort with urination | 0.7 | 1.6 | 2.1 |
| Pain in extremity | 1.4 | 2.0 | 1.7 |
| 1Genital mycotic infections include the
following adverse reactions, listed in order of frequency reported for females:
vulvovaginal mycotic infection, vaginal infection, vulvovaginal candidiasis,
vulvovaginitis, genital infection, genital candidiasis, fungal genital
infection, vulvitis, genitourinary tract infection, vulval abscess, and
vaginitis bacterial. (N for females: Placebo=677, dapagliflozin 5 mg=581,
dapagliflozin 10 mg=598). 2Urinary tract infections include the following adverse reactions, listed in order of frequency reported: urinary tract infection, cystitis, Escherichia urinary tract infection, genitourinary tract infection, pyelonephritis, trigonitis, urethritis, kidney infection, and prostatitis. 3Increased urination includes the following adverse reactions, listed in order of frequency reported: pollakiuria, polyuria, and urine output increased. 4Genital mycotic infections include the following adverse reactions, listed in order of frequency reported for males: balanitis, fungal genital infection, balanitis candida, genital candidiasis, genital infection male, penile infection, balanoposthitis, balanoposthitis infective, genital infection, posthitis. (N for males: Placebo=716, dapagliflozin 5 mg=564, dapagliflozin 10 mg=595). |
|||
The safety and tolerability of dapagliflozin 10 mg was also evaluated in a larger placebo-controlled study pool. This pool combined 13 placebo-controlled studies, including 3 monotherapy studies, 9 add-on to background antidiabetic therapy studies, and an initial combination with metformin study. Across these 13 studies, 2360 patients were treated once daily with dapagliflozin 10 mg for a mean duration of exposure of 22 weeks. The mean age of the population was 59 years and 4% were older than 75 years. Fifty-eight percent (58%) of the population were male; 84% were White, 9% were Asian, and 3% were Black or African American. At baseline, the population had diabetes for an average of 9 years, had a mean HbA1c of 8.2%, and 30% had established microvascular disease. Baseline renal function was normal or mildly impaired in 88% of patients and moderately impaired in 11% of patients (mean eGFR 82 mL/min/1.73 m²).
Dapagliflozin causes an osmotic diuresis, which may lead to reductions in intravascular volume. Adverse reactions related to volume depletion (including reports of dehydration, hypovolemia, orthostatic hypotension, or hypotension) are shown in Table 3 for the 12-study and 13-study, short-term, placebo-controlled pools [see WARNINGS AND PRECAUTIONS].
Table 3: Adverse Reactions of Volume Depletion1
in Clinical Studies with Dapagliflozin
| Pool of 12 Placebo-Controlled Studies | Pool of 13 Placebo-Controlled Studies | ||||
| Placebo | Dapagliflozin 5 mg | Dapagliflozin 10 mg | Placebo | Dapagliflozin 10 mg | |
| Overall population N (%) | N=1393 | N=1145 | N=1193 | N=2295 | N=2360 |
| 5 (0.4%) | 7 (0.6%) | 9 (0.8%) | 17 (0.7%) | 27 (1.1%) | |
| Patient Subgroup n (%) | |||||
| Patients on loop diuretics | n=55 | n=40 | n=31 | n=267 | n=236 |
| 1 (1.8%) | 0 | 3 (9.7%) | 4 (1.5%) | 6 (2.5%) | |
| Patients with moderate renal impairment with eGFR ≥ 30 and < 60 mL/min/1.73 m² | n=107 | n=107 | n=89 | n=268 | n=265 |
| 2 (1.9%) | 1 (0.9%) | 1 (1.1%) | 4 (1.5%) | 5 (1.9%) | |
| Patients ≥ 65 years of age | n=276 | n=216 | n=204 | n=711 | n=665 |
| 1 (0.4%) | 1 (0.5%) | 3 (1.5%) | 6 (0.8%) | 11 (1.7%) | |
| 1 Volume depletion includes reports of dehydration, hypovolemia, orthostatic hypotension, or hypotension. | |||||
Use of dapagliflozin was associated with increases in serum creatinine and decreases in eGFR (see Table 4). In patients with normal or mildly impaired renal function at baseline, serum creatinine and eGFR returned to baseline values at Week 24. Renal-related adverse reactions, including renal failure and blood creatinine increase, were more frequent in patients treated with dapagliflozin (see Table 5). Elderly patients and patients with impaired renal function were more susceptible to these adverse reactions (see Table 5). Sustained decreases in eGFR were seen in patients with moderate renal impairment (eGFR 30 to less than 60 mL/min/1.73 m²).
Table 4: Changes in Serum Creatinine and eGFR
Associated with Dapagliflozin in the Pool of 12 Placebo-Controlled Studies and
Moderate Renal Impairment Study
| Pool of 12 Placebo-Controlled Studies | ||||
| Placebo N=1393 |
Dapagliflozin 5 mg N=1145 |
Dapagliflozin 10 mg N=1193 |
||
| Baseline Mean | Serum Creatinine (mg/dL) | 0.853 | 0.860 | 0.847 |
| eGFR (mL/min/1.73 m²) | 86.0 | 85.3 | 86.7 | |
| Week 1 Change | Serum Creatinine (mg/dL) | -0.003 | 0.029 | 0.041 |
| eGFR (mL/min/1.73 m²) | 0.4 | -2.9 | -4.1 | |
| Week 24 Change | Serum Creatinine (mg/dL) | -0.005 | -0.001 | 0.001 |
| eGFR (mL/min/1.73 m²) | 0.8 | 0.8 | 0.3 | |
| Moderate Renal Impairment Study | ||||
| Placebo N=84 | Dapagliflozin 5 mg N=83 | Dapagliflozin 10 mg N=85 | ||
| Baseline Mean | Serum Creatinine (mg/dL) | 1.46 | 1.53 | 1.52 |
| eGFR (mL/min/1.73 m²) | 45.6 | 44.2 | 43.9 | |
| Week 1 Change | Serum Creatinine (mg/dL) | 0.01 | 0.13 | 0.18 |
| eGFR (mL/min/1.73 m²) | 0.5 | -3.8 | -5.5 | |
| Week 24 Change | Serum Creatinine (mg/dL) | 0.02 | 0.08 | 0.16 |
| eGFR (mL/min/1.73 m²) | 0.03 | -4.0 | -7.4 | |
| Week 52 Change | Serum Creatinine (mg/dL) | 0.10 | 0.06 | 0.15 |
| eGFR (mL/min/1.73 m²) | -2.6 | -4.2 | -7.3 | |
Table 5: Proportion of Patients with at Least One Renal Impairment-Related Adverse Reaction
| Baseline Characteristic | Pool of 6 Placebo-Controlled Studies (up to 104 weeks) 1 | Pool of 9 Placebo-Controlled Studies (up to 104 weeks)2 | |||
| Placebo | Dapagliflozin 5 mg | Dapagliflozin 10 mg | Placebo | Dapagliflozin 10 mg | |
| Overall population Patients (%) with at least one event | n=785 13 (1.7%) | n=767 14 (1.8%) | n=859 16 (1.9%) | n=1956 82 (4.2%) | n=2026 136 (6.7%) |
| 65 years of age and older Patients (%) with at least one event | n=190 4 (2.1%) | n=162 5 (3.1%) | n=159 6 (3.8%) | n=655 52 (7.9%) | n=620 87 (14.0%) |
| eGFR ≥ 30 and < 60 mL/min/1.73 m² Patients (%) with at least one event | n=77 5 (6.5%) | n=88 7 (8.0%) | n=75 9 (12.0%) | n=249 40 (16.1%) | n=251 71 (28.3%) |
| 65 years of age and older and eGFR ≥ 30 and < 60 mL/min/1.73 m² Patients (%) with at least one event | n=41 2 (4.9%) | n=43 3 (7.0%) | n=35 4 (11.4%) | n=141 27 (19.1%) | n=134 47 (35.1%) |
| 1Subset of patients from the pool of 12
placebo-controlled studies with long-term extensions. 2Subset of patients from the pool of 13 placebo-controlled studies with long-term extensions. |
|||||
The safety of dapagliflozin was evaluated in a study of patients with moderate renal impairment (eGFR 30 to less than 60 mL/min/1.73 m²). In this study 13 patients experienced bone fractures for treatment durations up to 104 weeks. No fractures occurred in the placebo group, 5 occurred in the dapagliflozin 5 mg group, and 8 occurred in the dapagliflozin 10 mg group. Eight of these 13 fractures were in patients who had a baseline eGFR of 30 to 45 mL/min/1.73 m². Eleven of the 13 fractures were reported within the first 52 weeks. There was no apparent pattern with respect to the anatomic site of fracture.
The frequency of hypoglycemia by study [see Clinical Studies] is shown in Table 6. Hypoglycemia was more frequent when dapagliflozin was added to sulfonylurea or insulin [see WARNINGS AND PRECAUTIONS].
Table 6: Incidence of Major1 and Minor2
Hypoglycemia in Placebo-Controlled Studies
| Placebo | Dapagliflozin 5 mg | Dapagliflozin 10 mg | |
| Add-on to Metformin 1 (24 weeks) | N=137 | N=137 | N=135 |
| Major [n (%)] | 0 | 0 | 0 |
| Minor [n (%)] | 0 | 2 (1.5) | 1 (0.7) |
| Active Control Add-on to Metformin versus Glipizide (52 weeks) | N=408 | - | N=406 |
| Major [n (%)] | 3 (0.7) | - | 0 |
| Minor [n (%)] | 147 (36.0) | - | 7 (1.7) |
| Add-on to DPP4 inhibitor (with or without Metformin) (24 weeks) | N=226 | - | N=225 |
| Major [n (%)] | 0 | - | 1 (0.4) |
| Minor [n (%)] | 3 (1.3) | - | 4 (1.8) |
| Add-on to Insulin with or without other OADs3 (24 weeks) | N=197 | N=212 | N=196 |
| Major [n (%)] | 1 (0.5) | 1 (0.5) | 1 (0.5) |
| Minor [n (%)] | 67 (34.0) | 92 (43.4) | 79 (40.3) |
| 1Major episodes of hypoglycemia were defined
as symptomatic episodes requiring external (third party) assistance due to
severe impairment in consciousness or behavior with a capillary or plasma
glucose value < 54 mg/dL and prompt recovery after glucose or glucagon
administration. 2Minor episodes of hypoglycemia were defined as either a symptomatic episode with a capillary or plasma glucose measurement < 63 mg/dL regardless of need for external assistance, or an asymptomatic capillary or plasma glucose measurement < 63 mg/dL that does not qualify as a major episode. 3OAD = oral antidiabetic therapy. |
|||
Genital mycotic infections were more frequent with dapagliflozin treatment. Genital mycotic infections were reported in 0.9% of patients on placebo, 5.7% on dapagliflozin 5 mg, and 4.8% on dapagliflozin 10 mg, in the 12-study placebo-controlled pool. Discontinuation from study due to genital infection occurred in 0% of placebo-treated patients and 0.2% of patients treated with dapagliflozin 10 mg. Infections were more frequently reported in females than in males (see Table 2). The most frequently reported genital mycotic infections were vulvovaginal mycotic infections in females and balanitis in males. Patients with a history of genital mycotic infections were more likely to have a genital mycotic infection during the study than those with no prior history (10.0%, 23.1%, and 25.0% versus 0.8%, 5.9%, and 5.0% on placebo, dapagliflozin 5 mg, and dapagliflozin 10 mg, respectively).
Hypersensitivity reactions (e.g., angioedema, urticaria, hypersensitivity) were reported with dapagliflozin treatment. Across the clinical program, serious anaphylactic reactions and severe cutaneous adverse reactions and angioedema were reported in 0.2% of comparator-treated patients and 0.3% of dapagliflozin-treated patients. If hypersensitivity reactions occur, discontinue use of dapagliflozin; treat per standard of care and monitor until signs and symptoms resolve.
Dapagliflozin
In the pool of 13 placebo-controlled studies, increases from baseline in mean hematocrit values were observed in dapagliflozin-treated patients starting at Week 1 and continuing up to Week 16, when the maximum mean difference from baseline was observed. At Week 24, the mean changes from baseline in hematocrit were -0.33% in the placebo group and 2.30% in the dapagliflozin 10 mg group. By Week 24, hematocrit values > 55% were reported in 0.4% of placebo-treated patients and 1.3% of dapagliflozin 10 mg-treated patients.
Dapagliflozin
In the pool of 13 placebo-controlled studies, increases from baseline in mean serum phosphorus levels were reported at Week 24 in dapagliflozin 10 mg-treated patients compared with placebo-treated patients (mean increases of 0.13 mg/dL versus -0.04 mg/dL, respectively). Higher proportions of patients with marked laboratory abnormalities of hyperphosphatemia ( ≥ 5.6 mg/dL if age 17-65 or ≥ 5.1 mg/dL if age ≥ 66) were reported in the dapagliflozin 10 mg group versus the placebo group at Week 24 (1.7% versus 0.9%, respectively).
Dapagliflozin
In the pool of 13 placebo-controlled studies, changes from baseline in mean lipid values were reported in dapagliflozintreated patients compared to placebo-treated patients. Mean percent change from baseline at Week 24 were 0.0% versus 2.5% for total cholesterol and -1.0% versus 2.9% for LDL cholesterol in the placebo and dapagliflozin 10 mg groups, respectively.
Metformin Hydrochloride
Metformin may lower serum vitamin B12 concentrations. Measurement of hematologic parameters on an annual basis is advised in patients on XIGDUO XR and any apparent abnormalities should be appropriately investigated and managed [see WARNINGS AND PRECAUTIONS].
Dapagliflozin
Additional adverse reactions have been identified during postapproval use of dapagliflozin. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Metformin Hydrochloride
Monitoring glycemic control with urine glucose tests is not recommended in patients taking SGLT2 inhibitors as SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. Use alternative methods to monitor glycemic control.
Monitoring glycemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycemic control.
Topiramate or other carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide or dichlorphenamide) frequently causes a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with XIGDUO XR may increase the risk for lactic acidosis. Consider more frequent monitoring of these patients.
Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors such as ranolazine, vandetanib, dolutegravir, and cimetidine) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see CLINICAL PHARMACOLOGY]. Consider the benefits and risks of concomitant use.
Alcohol is known to potentiate the effect of metformin on lactate metabolism. Warn patients against excessive alcohol intake while receiving XIGDUO XR.
Some medications can predispose to hyperglycemia and may lead to loss of glycemic control. These medications include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving XIGDUO XR, the patient should be observed closely for loss of glycemic control. When such drugs are withdrawn from a patient receiving XIGDUO XR, the patient should be observed closely for hypoglycemia.
In healthy volunteers, the pharmacokinetics of metformin and propranolol, and of metformin and ibuprofen were not affected when coadministered in single-dose interaction studies.
Included as part of the PRECAUTIONS section.
There have been post-marketing cases of metformin-associated lactic acidosis, including fatal cases. These cases had a subtle onset and were accompanied by nonspecific symptoms such as malaise, myalgias, abdominal pain, respiratory distress, or increased somnolence; however, hypothermia, hypotension and resistant bradyarrhythmias have occurred with severe acidosis.
Metformin-associated lactic acidosis was characterized by elevated blood lactate concentrations ( > 5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), and an increased lactate: pyruvate ratio; metformin plasma levels generally > 5 mcg/mL. Metformin decreases liver uptake of lactate increasing lactate blood levels which may increase the risk of lactic acidosis, especially in patients at risk.
If metformin-associated lactic acidosis is suspected, general supportive measures should be instituted promptly in a hospital setting, along with immediate discontinuation of XIGDUO XR.
In XIGDUO XR-treated patients with a diagnosis or strong suspicion of lactic acidosis, prompt hemodialysis is recommended to correct the acidosis and remove accumulated metformin (metformin hydrochloride is dialyzable, with a clearance of up to 170 mL/minute under good hemodynamic conditions). Hemodialysis has often resulted in reversal of symptoms and recovery.
Educate patients and their families about the symptoms of lactic acidosis and if these symptoms occur instruct them to discontinue XIGDUO XR and report these symptoms to their healthcare provider.
For each of the known and possible risk factors for metformin-associated lactic acidosis, recommendations to reduce the risk of and manage metformin-associated lactic acidosis are provided below:
The postmarketing metformin-associated lactic acidosis cases primarily occurred in patients with significant renal impairment. The risk of metformin accumulation and metformin-associated lactic acidosis increases with the severity of renal impairment because metformin is substantially excreted by the kidney. Clinical recommendations based upon the patient's renal function include [see DOSAGE AND ADMINISTRATION, and CLINICAL PHARMACOLOGY]:
Before initiating XIGDUO XR, obtain an estimated glomerular filtration rate (eGFR).
XIGDUO XR is contraindicated in patients with an eGFR less than 60 mL/minute/1.73 m² [see CONTRAINDICATIONS].
Obtain an eGFR at least annually in all patients taking XIGDUO XR. In patients at increased risk for the development of renal impairment (e.g., the elderly), renal function should be assessed more frequently.
The concomitant use of XIGDUO XR with specific drugs may increase the risk of metforminassociated lactic acidosis: those that impair renal function, result in significant hemodynamic change, interfere with acid-base balance or increase metformin accumulation (e.g. cationic drugs) [see DRUG INTERACTIONS]. Therefore, consider more frequent monitoring of patients.
The risk of metformin-associated lactic acidosis increases with the patient's age because elderly patients have a greater likelihood of having hepatic, renal, or cardiac impairment than younger patients. Assess renal function more frequently in elderly patients [see Use in Specific Populations].
Radiological Studies with Contrast: Administration of intravascular iodinated contrast agents in metformin-treated patients has led to an acute decrease in renal function and the occurrence of lactic acidosis. Stop XIGDUO XR at the time of, or prior to, an iodinated contrast imaging procedure in patients with a history of hepatic impairment, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure, and restart XIGDUO XR if renal function is stable.
Withholding of food and fluids during surgical or other procedures may increase the risk for volume depletion, hypotension and renal impairment. XIGDUO XR should be temporarily discontinued while patients have restricted food and fluid intake.
Several of the postmarketing cases of metformin-associated lactic acidosis occurred in the setting of acute congestive heart failure (particularly when accompanied by hypoperfusion and hypoxemia). Cardiovascular collapse (shock), acute myocardial infarction, sepsis, and other conditions associated with hypoxemia have been associated with lactic acidosis and may also cause prerenal azotemia. When such events occur, discontinue XIGDUO XR.
Alcohol potentiates the effect of metformin on lactate metabolism and this may increase the risk of metformin-associated lactic acidosis. Warn patients against excessive alcohol intake while receiving XIGDUO XR.
Patients with hepatic impairment have developed with cases of metformin-associated lactic acidosis. This may be due to impaired lactate clearance resulting in higher lactate blood levels. Therefore, avoid use of XIGDUO XR in patients with clinical or laboratory evidence of hepatic disease.
Dapagliflozin causes intravascular volume contraction. Symptomatic hypotension can occur after initiating dapagliflozin [see ADVERSE REACTIONS], particularly in patients with impaired renal function (eGFR less than 60 mL/min/1.73 m²), elderly patients, or patients on loop diuretics.
Before initiating XIGDUO XR in patients with one or more of these characteristics, volume status should be assessed and corrected. Monitor for signs and symptoms of hypotension after initiating therapy.
Reports of ketoacidosis, a serious life-threatening condition requiring urgent hospitalization have been identified in postmarketing surveillance in patients with type 1 and type 2 diabetes mellitus taking sodium-glucose co transporter 2 (SGLT2) inhibitors, including dapagliflozin. Fatal cases of ketoacidosis have been reported in patients taking dapagliflozin. XIGDUO XR is not indicated for the treatment of patients with type 1 diabetes mellitus [see INDICATIONS AND USAGE].
Patients treated with XIGDUO XR who present with signs and symptoms consistent with severe metabolic acidosis should be assessed for ketoacidosis regardless of blood glucose levels as ketoacidosis associated with XIGDUO XR may be present even if blood glucose levels are less than 250 mg/dL. If ketoacidosis is suspected, XIGDUO XR should be discontinued, the patient should be evaluated and prompt treatment should be instituted. Treatment of ketoacidosis may require insulin, fluid and carbohydrate replacement.
In many of the postmarketing reports, and particularly in patients with type 1 diabetes, the presence of ketoacidosis was not immediately recognized and institution of treatment was delayed because presenting blood glucose levels were below those typically expected for diabetic ketoacidosis (often less than 250 mg/dL). Signs and symptoms at presentation were consistent with dehydration and severe metabolic acidosis and included nausea, vomiting, abdominal pain, generalized malaise, and shortness of breath. In some but not all cases, factors predisposing to ketoacidosis such as insulin dose reduction, acute febrile illness, reduced caloric intake due to illness or surgery, pancreatic disorders suggesting insulin deficiency (e.g., type 1 diabetes, history of pancreatitis or pancreatic surgery), and alcohol abuse were identified.
Before initiating XIGDUO XR, consider factors in the patient history that may predispose to ketoacidosis including pancreatic insulin deficiency from any cause, caloric restriction and alcohol abuse. In patients treated with XIGDUO XR consider monitoring for ketoacidosis and temporarily discontinuing XIGDUO XR in clinical situations known to predispose to ketoacidosis (e.g., prolonged fasting due to acute illness or surgery).
Dapagliflozin causes intravascular volume contraction [see Lactic Acidosis], and can cause renal impairment [see ADVERSE REACTIONS]. There have been postmarketing reports of acute kidney injury, some requiring hospitalization and dialysis, in patients receiving dapagliflozin: some reports involved patients younger than 65 years of age.
Before initiating XIGDUO XR, consider factors that may predispose patients to acute kidney injury including hypovolemia, chronic renal insufficiency, congestive heart failure, and concomitant medications (diuretics, ACE inhibitors, ARBs, NSAIDs). Consider temporarily discontinuing XIGDUO XR in any setting of reduced oral intake (such as acute illness or fasting) or fluid losses (gastrointestinal illness or excessive heat exposure); monitor patients for signs and symptoms of acute kidney injury. If acute kidney injury occurs, discontinue XIGDUO XR promptly and institute treatment.
Dapagliflozin increases serum creatinine and decreases eGFR. Elderly patients and patients with impaired renal function may be more susceptible to these changes. Adverse reactions related to renal function can occur after initiating XIGDUO XR [see ADVERSE REACTIONS]. Renal function should be evaluated prior to initiation of XIGDUO XR and monitored periodically thereafter. XIGDUO XR is contraindicated in patients with an eGFR below 60 mL/min/1.73 m² [see DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, Lactic Acidosis and Use in Specific Populations].
There have been postmarketing reports of serious urinary tract infections including urosepsis and pyelonephritis requiring hospitalization in patients receiving SGLT2 inhibitors, including dapagliflozin. Treatment with SGLT2 inhibitors increases the risk for urinary tract infections. Evaluate patients for signs and symptoms of urinary tract infections and treat promptly, if indicated [see ADVERSE REACTIONS].
Insulin and insulin secretagogues are known to cause hypoglycemia. Dapagliflozin can increase the risk of hypoglycemia when combined with insulin or an insulin secretagogue [see ADVERSE REACTIONS]. Therefore, a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when these agents are used in combination with XIGDUO XR.
Hypoglycemia does not occur in patients receiving metformin alone under usual circumstances of use, but could occur when caloric intake is deficient, when strenuous exercise is not compensated by caloric supplementation, or during concomitant use with other glucose-lowering agents (such as sulfonylureas and insulin) or ethanol. Elderly, debilitated, or malnourished patients, and those with adrenal or pituitary insufficiency or alcohol intoxication are particularly susceptible to hypoglycemic effects. Hypoglycemia may be difficult to recognize in the elderly and in people who are taking betaadrenergic blocking drugs.
In controlled clinical trials of metformin of 29-week duration, a decrease to subnormal levels of previously normal serum vitamin B12 levels, without clinical manifestations, was observed in approximately 7% of patients. This decrease, possibly due to interference with B12 absorption from the B12-intrinsic factor complex is, however, very rarely associated with anemia and appears to be rapidly reversible with discontinuation of metformin or vitamin B12 supplementation. Measurement of hematologic parameters on an annual basis is advised in patients on XIGDUO XR and any apparent abnormalities should be appropriately investigated and managed [see ADVERSE REACTIONS].
Certain individuals (those with inadequate vitamin B12 or calcium intake or absorption) appear to be predisposed to developing subnormal vitamin B12 levels. In these patients, routine serum vitamin B12 measurements at 2-to 3-year intervals may be useful.
Dapagliflozin increases the risk of genital mycotic infections. Patients with a history of genital mycotic infections were more likely to develop genital mycotic infections [see ADVERSE REACTIONS]. Monitor and treat appropriately.
Increases in LDL-C occur with dapagliflozin [see ADVERSE REACTIONS]. Monitor LDL-C and treat per standard of care after initiating XIGDUO XR.
Across 22 clinical studies, newly diagnosed cases of bladder cancer were reported in 10/6045 patients (0.17%) treated with dapagliflozin and 1/3512 patient (0.03%) treated with placebo/comparator. After excluding patients in whom exposure to study drug was less than one year at the time of diagnosis of bladder cancer, there were 4 cases with dapagliflozin and no cases with placebo/comparator. Bladder cancer risk factors and hematuria (a potential indicator of pre-existing tumors) were balanced between treatment arms at baseline. There were too few cases to determine whether the emergence of these events is related to dapagliflozin.
There are insufficient data to determine whether dapagliflozin has an effect on pre-existing bladder tumors. Consequently, XIGDUO XR should not be used in patients with active bladder cancer. In patients with prior history of bladder cancer, the benefits of glycemic control versus unknown risks for cancer recurrence with XIGDUO XR should be considered.
There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with XIGDUO XR.
See FDA-approved Patient Labeling (Medication Guide).
Instruct patients to read the Medication Guide before starting treatment with XIGDUO XR and to reread it each time the prescription is renewed.
Inform patients of the potential risks and benefits of XIGDUO XR and of alternative modes of therapy. Also inform patients about the importance of adherence to dietary instructions, regular physical activity, periodic blood glucose monitoring and HbA1c testing, recognition and management of hypoglycemia and hyperglycemia, and assessment of diabetes complications. Advise patients to seek medical advice promptly during periods of stress such as fever, trauma, infection, or surgery, as medication requirements may change.
Inform patients that the incidence of hypoglycemia may be increased when XIGDUO XR is added to an insulin secretagogue (e.g., sulfonylurea) or insulin [see WARNINGS AND PRECAUTIONS].
Instruct patient to immediately inform her healthcare provider if she is pregnant or plans to become pregnant. Based on animal data, XIGDUO XR may cause fetal harm in the second and third trimesters of pregnancy.
Instruct patient to immediately inform her healthcare provider if she is breastfeeding or planning to breastfeed. It is not known if XIGDUO XR is excreted in breast milk; however, based on animal data, XIGDUO XR may cause harm to nursing infants.
Inform patients that the most common adverse reactions associated with use of XIGDUO XR are female genital mycotic infections, nasopharyngitis, urinary tract infections, diarrhea, headache, nausea, and vomiting.
Instruct patients that XIGDUO XR must be swallowed whole and not crushed or chewed, and that the inactive ingredients may occasionally be eliminated in the feces as a soft mass that may resemble the original tablet.
Instruct patients to take XIGDUO XR only as prescribed. If a dose is missed, advise patients to take it as soon as it is remembered unless it is almost time for the next dose, in which case patients should skip the missed dose and take the medicine at the next regularly scheduled time. Advise patients not to take 2 tablets of XIGDUO XR at the same time, unless otherwise instructed by their healthcare provider.
Inform patients of the risks of lactic acidosis due to the metformin component and its symptoms and conditions that predispose to its development [see WARNINGS AND PRECAUTIONS]. Advise patients to discontinue XIGDUO XR immediately and to promptly notify their healthcare provider if unexplained hyperventilation, myalgia, malaise, unusual somnolence, dizziness, slow or irregular heartbeat, sensation of feeling cold (especially in the extremities), or other nonspecific symptoms occur. Gastrointestinal symptoms are common during initiation of metformin treatment and may occur during initiation of XIGDUO XR therapy; however, inform patients to consult their physician if they develop unexplained symptoms. Although gastrointestinal symptoms that occur after stabilization are unlikely to be drug related, such an occurrence of symptoms should be evaluated to determine if it may be due to lactic acidosis or other serious disease.
Counsel patients against excessive alcohol intake while receiving XIGDUO XR [see WARNINGS AND PRECAUTIONS].
Inform patients about the importance of regular testing of renal function and hematological parameters when receiving treatment with XIGDUO XR [see CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS].
Instruct patients to inform their doctor that they are taking XIGDUO XR prior to any surgical or radiological procedure, as temporary discontinuation of XIGDUO XR may be required until renal function has been confirmed to be normal [see WARNINGS AND PRECAUTIONS].
Inform patients that symptomatic hypotension may occur with XIGDUO XR and advise them to contact their healthcare provider if they experience such symptoms [see WARNINGS AND PRECAUTIONS]. Inform patients that dehydration may increase the risk for hypotension, and to have adequate fluid intake.
Inform patients that ketoacidosis is a serious life-threatening condition. Cases of ketoacidosis have been reported during use of dapagliflozin. Instruct patients to check ketones (when possible) if symptoms consistent with ketoacidosis occur even if blood glucose is not elevated. If symptoms of ketoacidosis (including nausea, vomiting, abdominal pain, tiredness, and labored breathing) occur, instruct patients to discontinue XIGDUO XR and seek medical advice immediately [see WARNINGS AND PRECAUTIONS].
Inform patients that acute kidney injury has been reported during use of dapagliflozin. Advise patients to seek medical advice immediately if they have reduced oral intake (due to acute illness or fasting) or increased fluid losses (due to vomiting, diarrhea, or excessive heat exposure), as it may be appropriate to temporarily discontinue XIGDUO XR use in those settings [see WARNINGS AND PRECAUTIONS].
Inform patients of the potential for urinary tract infections, which may be serious. Provide them with information on the symptoms of urinary tract infections. Advise them to seek medical advice promptly if such symptoms occur [see WARNINGS AND PRECAUTIONS].
Inform female patients that vaginal yeast infections may occur and provide them with information on the signs and symptoms of vaginal yeast infections. Advise them of treatment options and when to seek medical advice [see WARNINGS AND PRECAUTIONS].
Inform male patients that yeast infections of the penis (e.g., balanitis or balanoposthitis) may occur, especially in patients with prior history. Provide them with information on the signs and symptoms of balanitis and balanoposthitis (rash or redness of the glans or foreskin of the penis). Advise them of treatment options and when to seek medical advice [see WARNINGS AND PRECAUTIONS].
Inform patients that serious hypersensitivity reactions (e.g., urticaria and angioedema) have been reported with the components of XIGDUO XR. Advise patients to immediately report any signs or symptoms suggesting allergic reaction or angioedema, and to take no more of the drug until they have consulted prescribing physicians.
Inform patients to promptly report any signs of macroscopic hematuria or other symptoms potentially related to bladder cancer.
Due to the mechanism of action of dapagliflozin, patients taking XIGDUO XR will test positive for glucose in their urine.
No animal studies have been conducted with XIGDUO XR to evaluate carcinogenesis, mutagenesis, or impairment of fertility. The following data are based on the findings in the studies with dapagliflozin and metformin individually.
Dapagliflozin did not induce tumors in either mice or rats at any of the doses evaluated in 2-year carcinogenicity studies. Oral doses in mice consisted of 5, 15, and 40 mg/kg/day in males and 2, 10, and 20 mg/kg/day in females, and oral doses in rats were 0.5, 2, and 10 mg/kg/day for both males and females. The highest doses evaluated in mice were approximately 72 times (males) and 105 times (females) the clinical dose of 10 mg/day based on AUC exposure. In rats, the highest dose was approximately 131 times (males) and 186 times (females) the clinical dose of 10 mg/day based on AUC exposure.
Dapagliflozin was negative in the Ames mutagenicity assay and was positive in a series of in vitro clastogenicity assays in the presence of S9 activation and at concentrations ≥ 100 μg/mL. Dapagliflozin was negative for clastogenicity in a series of in vivo studies evaluating micronuclei or DNA repair in rats at exposure multiples > 2100 times the clinical dose.
There was no carcinogenicity or mutagenicity signal in animal studies, suggesting that dapagliflozin does not represent a genotoxic risk to humans.
Dapagliflozin had no effects on mating, fertility, or early embryonic development in treated male or female rats at exposure multiples ≤ 1708 and 998 times the maximum recommended human doses in males and females, respectively.
Long-term carcinogenicity studies have been performed in rats (dosing duration of 104 weeks) and mice (dosing duration of 91 weeks) at doses up to and including 900 and 1500 mg/kg/day, respectively. These doses are both approximately 4 times the MRHD of 2000 mg based on body surface area comparisons. No evidence of carcinogenicity with metformin was found in either male or female mice. Similarly, there was no tumorigenic potential observed with metformin in male rats. There was, however, an increased incidence of benign stromal uterine polyps in female rats treated with 900 mg/kg/day.
There was no evidence of a mutagenic potential of metformin in the following in vitro tests: Ames test (S. typhimurium), gene mutation test (mouse lymphoma cells), or chromosomal aberrations test (human lymphocytes). Results in the in vivo mouse micronucleus test were also negative.
Fertility of male or female rats was unaffected by metformin when administered at doses as high as 600 mg/kg/day, which is approximately 3 times the MRHD based on body surface area comparisons.
There are no adequate and well-controlled studies of XIGDUO XR or its individual components in pregnant women. Based on results of reproductive and developmental toxicity studies in animals, dapagliflozin, a component of XIGDUO XR, may affect renal development and maturation. In a juvenile rat study, increased incidence and/or severity of renal pelvic and tubular dilatations were evident at the lowest tested dose which was approximately 15 times clinical exposure from a 10 mg dose.
These outcomes occurred with drug exposures during periods of animal development that correlate with the late second and third trimesters of human pregnancy. During pregnancy, consider appropriate alternative therapies, especially during the second and third trimesters. XIGDUO XR should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
In a juvenile toxicity study, when dapagliflozin was dosed directly to young rats from postnatal day (PND) 21 until PND 90 at doses of 1, 15, or 75 mg/kg/day, increased kidney weights and renal pelvic and tubular dilatations were reported at all levels. Exposure at the lowest tested dose was 15 times the maximum clinical dose, based on AUC. The renal pelvic and tubular dilatations observed in juvenile animals did not fully reverse within the approximate 1-month recovery period.
In a prenatal and postnatal development study, maternal rats were dosed from gestation day 6 through lactation day 21 at doses of 1, 15, or 75 mg/kg/day, and pups were indirectly exposed in utero and throughout lactation. Increased incidence or severity of renal pelvic dilatation was observed in adult offspring of treated dams at 75 mg/kg/day (maternal and pup dapagliflozin exposures were 1415 times and 137 times, respectively, the human values at the clinical dose). Dose-related reductions in pup body weights were observed at doses ≥ 1 mg/kg/day (approximately ≥ 19 times the clinical dose). No adverse effects on developmental endpoints were noted at 1 mg/kg/day, or approximately 19 times the clinical dose.
In embryo-fetal development studies in rats and rabbits, dapagliflozin was administered for intervals coinciding with the first trimester period of organogenesis in humans. No developmental toxicities were observed in rabbits at any dose tested. In rats, dapagliflozin was neither embryolethal nor teratogenic at doses up to 75 mg/kg/day or 1441 times the maximum clinical dose of 10 mg. At higher doses in rats, malformations of blood vessels, ribs, vertebrae, manubria, and skeletal variations in fetuses at ≥ 150 mg/kg or 2344 times the 10 mg clinical dose were observed.
Metformin was not teratogenic in rats and rabbits at doses up to 600 mg/kg/day. This represents an exposure of about 2 and 6 times the MRHD of 2000 mg based on body surface area comparisons for rats and rabbits, respectively. Determination of fetal concentrations demonstrated a partial placental barrier to metformin.
It is not known whether XIGDUO XR is excreted in human milk. In studies performed with the individual components, both dapagliflozin (reaching levels 0.49 times that found in maternal plasma) and metformin are excreted in the milk of lactating rats.
Data in juvenile rats directly exposed to dapagliflozin showed risk to the developing kidney (renal pelvic and tubular dilatations) during maturation. Since human kidney maturation occurs in utero and in the first 2 years of life when lactational exposure may occur, there may be risk to the developing human kidney. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from dapagliflozin, a decision should be made whether to discontinue nursing or to discontinue XIGDUO XR, taking into account the importance of the drug to the mother.
Safety and effectiveness of XIGDUO XR in pediatric patients under 18 years of age have not been established.
No XIGDUO XR dosage change is recommended based on age. More frequent assessment of renal function is recommended in elderly patients.
A total of 1424 (24%) of the 5936 dapagliflozin-treated patients were 65 years and over and 207 (3.5%) patients were 75 years and older in a pool of 21 double-blind, controlled, clinical safety and efficacy studies of dapagliflozin. After controlling for level of renal function (eGFR), efficacy was similar for patients under age 65 years and those 65 years and older. In patients ≥ 65 years of age, a higher proportion of patients treated with dapagliflozin had adverse reactions related to volume depletion and renal impairment or failure compared to patients treated with placebo [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS].
Controlled clinical studies of metformin did not include sufficient numbers of elderly patients to determine whether they respond differently than younger patients, although other reported clinical experience has not identified differences in responses between the elderly and young patients. Metformin is known to be substantially excreted by the kidney and because the risk of lactic acidosis with metformin is greater in patients with moderately to severely impaired renal function. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of lactic acidosis. Assess renal function more frequently in elderly patients [see WARNINGS AND PRECAUTIONS, and CLINICAL PHARMACOLOGY].
The pool of 21 double-blind, active-and placebo-controlled clinical safety and efficacy studies (dapagliflozin as monotherapy or in combination with other antidiabetic therapies) included 53% (4906/9339) of patients with mild renal impairment. The safety profile in patients with mild renal impairment is similar to that in the overall population.
Use of metformin in patients with hepatic impairment has been associated with some cases of lactic acidosis. XIGDUO XR is not recommended in patients with hepatic impairment [see WARNINGS AND PRECAUTIONS].
There were no reports of overdose during the clinical development program for dapagliflozin. In the event of an overdose, contact the Poison Control Center. It is also reasonable to employ supportive measures as dictated by the patient's clinical status. The removal of dapagliflozin by hemodialysis has not been studied.
Overdose of metformin hydrochloride has occurred, including ingestion of amounts > 50 grams. Hypoglycemia was reported in approximately 10% of cases, but no causal association with metformin hydrochloride has been established. Lactic acidosis has been reported in approximately 32% of metformin overdose cases [see WARNINGS AND PRECAUTIONS]. Metformin is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions. Therefore, hemodialysis may be useful for removal of accumulated drug from patients in whom metformin overdosage is suspected.
XIGDUO XR is contraindicated in patients with:
XIGDUO XR combines two antihyperglycemic agents with complementary mechanisms of action to improve glycemic control in patients with type 2 diabetes: dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and metformin hydrochloride, a biguanide.
Sodium-glucose cotransporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
Metformin improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Metformin does not produce hypoglycemia in either patients with type 2 diabetes or in healthy subjects, except in unusual circumstances [see WARNINGS AND PRECAUTIONS], and does not cause hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may actually decrease.
Dapagliflozin
Increases in the amount of glucose excreted in the urine were observed in healthy subjects and in patients with type 2 diabetes mellitus following the administration of dapagliflozin (see Figure 1). Dapagliflozin doses of 5 or 10 mg per day in patients with type 2 diabetes mellitus for 12 weeks resulted in excretion of approximately 70 grams of glucose in the urine per day. A near maximum glucose excretion was observed at the dapagliflozin daily dose of 20 mg. This urinary glucose excretion with dapagliflozin also results in increases in urinary volume [see ADVERSE REACTIONS].
Figure 1: Scatter Plot and Fitted Line of Change from
Baseline in 24-Hour Urinary Glucose Amount versus Dapagliflozin Dose in Healthy
Subjects and Subjects with Type 2 Diabetes Mellitus (T2DM) (Semi-Log Plot)
 |
Dapagliflozin was not associated with clinically meaningful prolongation of QTc interval at daily doses up to 150 mg (15 times the recommended dose) in a study of healthy subjects. In addition, no clinically meaningful effect on QTc interval was observed following single doses of up to 500 mg (50 times the recommended dose) dapagliflozin in healthy subjects.
XIGDUO XR combination tablets are considered to be bioequivalent to coadministration of corresponding doses of dapagliflozin (FARXIGA®) and metformin hydrochloride extended-release (GLUCOPHAGE® XR) administered together as individual tablets.
The administration of XIGDUO XR in healthy subjects after a standard meal compared to the fasted state resulted in the same extent of exposure for both dapagliflozin and metformin extended-release. Compared to the fasted state, the standard meal resulted in 35% reduction and a delay of 1 to 2 hours in the peak plasma concentrations of dapagliflozin. This effect of food is not considered to be clinically meaningful. Food has no relevant effect on the pharmacokinetics of metformin when administered as XIGDUO XR combination tablets.
Dapagliflozin
Following oral administration of dapagliflozin, the maximum plasma concentration (Cmax) is usually attained within 2 hours under fasting state. The Cmax and AUC values increase dose proportionally with increase in dapagliflozin dose in the therapeutic dose range. The absolute oral bioavailability of dapagliflozin following the administration of a 10 mg dose is 78%. Administration of dapagliflozin with a high-fat meal decreases its Cmax by up to 50% and prolongs Tmax by approximately 1 hour, but does not alter AUC as compared with the fasted state. These changes are not considered to be clinically meaningful and dapagliflozin can be administered with or without food.
Metformin Hydrochloride
Following a single oral dose of metformin extended-release, Cmax is achieved with a median value of 7 hours and a range of 4 to 8 hours. The extent of metformin absorption (as measured by AUC) from the metformin extended-release tablet increased by approximately 50% when given with food. There was no effect of food on Cmax and Tmax of metformin.
Dapagliflozin
Dapagliflozin is approximately 91% protein bound. Protein binding is not altered in patients with renal or hepatic impairment.
Metformin Hydrochloride
Distribution studies with extended-release metformin have not been conducted; however, the apparent volume of distribution (V/F) of metformin following single oral doses of immediate-release metformin 850 mg averaged 654 ± 358 L. Metformin is negligibly bound to plasma proteins, in contrast to sulfonylureas, which are more than 90% protein bound. Metformin partitions into erythrocytes.
Dapagliflozin
The metabolism of dapagliflozin is primarily mediated by UGT1A9; CYP-mediated metabolism is a minor clearance pathway in humans. Dapagliflozin is extensively metabolized, primarily to yield dapagliflozin 3-O-glucuronide, which is an inactive metabolite. Dapagliflozin 3-O-glucuronide accounted for 61% of a 50 mg [14C]-dapagliflozin dose and is the predominant drug-related component in human plasma.
Metformin Hydrochloride
Intravenous single-dose studies in healthy subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been identified in humans) or biliary excretion.
Metabolism studies with extended-release metformin tablets have not been conducted.
Dapagliflozin
Dapagliflozin and related metabolites are primarily eliminated via the renal pathway. Following a single 50 mg dose of [14C]-dapagliflozin, 75% and 21% total radioactivity is excreted in urine and feces, respectively. In urine, less than 2% of the dose is excreted as parent drug. In feces, approximately 15% of the dose is excreted as parent drug. The mean plasma terminal half-life (t½) for dapagliflozin is approximately 12.9 hours following a single oral dose of dapagliflozin 10 mg.
Metformin Hydrochloride
Renal clearance is approximately 3.5 times greater than creatinine clearance, which indicates that tubular secretion is the major route of metformin elimination. Following oral administration, approximately 90% of the absorbed drug is eliminated via the renal route within the first 24 hours, with a plasma elimination half-life of approximately 6.2 hours. In blood, the elimination half-life is approximately 17.6 hours, suggesting that the erythrocyte mass may be a compartment of distribution.
Dapagliflozin
At steady-state (20 mg once-daily dapagliflozin for 7 days), patients with type 2 diabetes with mild, moderate, or severe renal impairment (as determined by eGFR) had geometric mean systemic exposures of dapagliflozin that were 45%, 2.04fold, and 3.03-fold higher, respectively, as compared to patients with type 2 diabetes with normal renal function. Higher systemic exposure of dapagliflozin in patients with type 2 diabetes mellitus with renal impairment did not result in a correspondingly higher 24-hour glucose excretion. The steady-state 24-hour urinary glucose excretion in patients with type 2 diabetes and mild, moderate, and severe renal impairment was 42%, 80%, and 90% lower, respectively, than in patients with type 2 diabetes with normal renal function. The impact of hemodialysis on dapagliflozin exposure is not known [see DOSAGE AND ADMINISTRATION, WARNINGS AND PRECAUTIONS, and Use in Specific Populations].
Metformin Hydrochloride
In patients with decreased renal function, the plasma and blood half-life of metformin is prolonged and the renal clearance is decreased [see CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS].
Dapagliflozin
In patients with mild and moderate hepatic impairment (Child-Pugh Classes A and B), mean Cmax and AUC of dapagliflozin were up to 12% and 36% higher, respectively, as compared to healthy matched control subjects following single-dose administration of 10 mg dapagliflozin. These differences were not considered to be clinically meaningful. In patients with severe hepatic impairment (Child-Pugh Class C), mean Cmax and AUC of dapagliflozin were up to 40% and 67% higher, respectively, as compared to healthy matched controls.
Metformin Hydrochloride
No pharmacokinetic studies of metformin have been conducted in patients with hepatic impairment.
Dapagliflozin
Based on a population pharmacokinetic analysis, age does not have a clinically meaningful effect on systemic exposures of dapagliflozin; thus, no dose adjustment is recommended.
Metformin Hydrochloride
Limited data from controlled pharmacokinetic studies of metformin in healthy elderly subjects suggests that total plasma clearance of metformin is decreased, the half-life is prolonged, and Cmax is increased, compared to healthy young subjects. From these data, it appears that the change in metformin pharmacokinetics with aging is primarily accounted for by a change in renal function.
Pharmacokinetics of XIGDUO XR in the pediatric population has not been studied.
Dapagliflozin
Based on a population pharmacokinetic analysis, gender does not have a clinically meaningful effect on systemic exposures of dapagliflozin; thus, no dose adjustment is recommended.
Metformin Hydrochloride
Metformin pharmacokinetic parameters did not differ significantly between healthy subjects and patients with type 2 diabetes when analyzed according to gender (males=19, females=16). Similarly, in controlled clinical studies in patients with type 2 diabetes, the antihyperglycemic effect of metformin was comparable in males and females.
Dapagliflozin
Based on a population pharmacokinetic analysis, race (White, Black, or Asian) does not have a clinically meaningful effect on systemic exposures of dapagliflozin; thus, no dose adjustment is recommended.
Metformin Hydrochloride
No studies of metformin pharmacokinetic parameters according to race have been performed. In controlled clinical studies of metformin in patients with type 2 diabetes, the antihyperglycemic effect was comparable in Whites (n=249), Blacks (n=51), and Hispanics (n=24).
Dapagliflozin
Based on a population pharmacokinetic analysis, body weight does not have a clinically meaningful effect on systemic exposures of dapagliflozin; thus, no dose adjustment is recommended.
Specific pharmacokinetic drug interaction studies with XIGDUO XR have not been performed, although such studies have been conducted with the individual dapagliflozin and metformin components.
Dapagliflozin
In in vitro studies, dapagliflozin and dapagliflozin 3-O-glucuronide neither inhibited CYP 1A2, 2C9, 2C19, 2D6, 3A4, nor induced CYP 1A2, 2B6, or 3A4. Dapagliflozin is a weak substrate of the P-glycoprotein (P-gp) active transporter, and dapagliflozin 3-O-glucuronide is a substrate for the OAT3 active transporter. Dapagliflozin or dapagliflozin 3-Oglucuronide did not meaningfully inhibit P-gp, OCT2, OAT1, or OAT3 active transporters. Overall, dapagliflozin is unlikely to affect the pharmacokinetics of concurrently administered medications that are P-gp, OCT2, OAT1, or OAT3 substrates.
Table 7 shows the effect of other coadministered drugs on metformin.
Table 7: Effect of Coadministered Drug on Plasma
Metformin Systemic Exposure
| Coadministered Drug (Dose Regimen)1 | Metformin (Dose Regimen)1 | Metformin | |
| Change2 in AUC3 | Change2 in Cmax | ||
| No dosing adjustments required for the following: | |||
| Glyburide (5 mg) | 850 mg | ↓9%4 | ↓7 % |
| Furosemide (40 mg) | 850 mg | ↑15%4 | ↑22%4 |
| Nifedipine (10 mg) | 850 mg | ↑9% | ↑20% |
| Propranolol (40 mg) | 850 mg | ↓10% | ↓6% |
| Ibuprofen (400 mg) | 850 mg | ↑5 4 | ↑7%4 |
| Drugs eliminated by renal tubular secretion may increase the accumulation of metformin [see DRUG INTERACTIONS]. | |||
| Cimetidine (400 mg) | 850 mg | ↑40% | ↑60% |
| 1All metformin and coadministered drugs were
given as single doses. 2Percent change (with/without coadministered drug and no change = 0%); ↑; and ↓ indicate the exposure increase and decrease, respectively. 3AUC = AUC(INF). 4Ratio of arithmetic means. |
|||
Table 8 shows the effect of metformin on other coadministered drugs.
Table 8: Effect of Metformin
on Coadministered Drug Systemic Exposure
| Coadministered Drug (Dose Regimen) 1 | Metformin (Dose Regimen) 1 | Coadministered Drug | |
| Change2 in AUC3 | Change2 in Cmax | ||
| No dosing adjustments required for the following: | |||
| Glyburide (5 mg) | 850 mg | ↓22%4 | ↓37%4 |
| Furosemide (40 mg) | 850 mg | ↓12%4 | ↓31%4 |
| Nifedipine (10 mg) | 850 mg | ↑10%5 | ↑8% |
| Propranolol (40 mg) | 850 mg | ↑1%5 | ↑2% |
| Ibuprofen (400 mg) | 850 mg | ↓3%6 | ↑1%6 |
| Cimetidine (400 mg) | 850 mg | ↓5%5 | ↑1% |
| 5All metformin and coadministered drugs were
given as single doses. 6Percent change (with/without coadministered drug and no change = 0%); ↑; and ↓ indicate the exposure increase and decrease, respectively. 7AUC = AUC(INF) unless otherwise noted. 8Ratio of arithmetic means, p-value of difference < 0.05. 9AUC(0-24 hr) reported. 10Ratio of arithmetic means. |
|||
Table 9 shows the effect of coadministered drugs on dapagliflozin. No dose adjustments are recommended for dapagliflozin.
Table 9: Effects of Coadministered Drugs on
Dapagliflozin Systemic Exposure
| Coadministered Drug (Dose Regimen) 1 | Dapagliflozin (Dose Regimen) 1 | Dapagliflozin | |
| Change2 in AUC3 | Change2 in Cmax | ||
| No dosing adjustments required for the following: | |||
| Oral Antidiabetic Agents | |||
| Metformin (1000 mg) | 20 mg | ↓1% | ↓7% |
| Pioglitazone (45 mg) | 50 mg | 0% | ↑9% |
| Sitagliptin (100 mg) | 20 mg | ↑8% | ↓4% |
| Glimepiride (4 mg) | 20 mg | ↓1% | ↑1% |
| Voglibose (0.2 mg three times daily) | 10 mg | ↑1% | ↑4% |
| Cardiovascular Agents | |||
| Hydrochlorothiazide (25 mg) | 50 mg | ↑7% | ↓1% |
| Bumetanide (1 mg) | 10 mg once daily for 7 days | ↑5% | ↑8% |
| Valsartan (320 mg) | 20 mg | ↑2% | ↓12% |
| Simvastatin (40 mg) | 20 mg | ↓1% | ↓2% |
| Anti-infective Agent | |||
| Rifampin (600 mg once daily for 6 days) | 10 mg | ↓22% | ↓7% |
| Non-Steroidal Anti-inflammatory Agent | |||
| Mefenamic Acid (loading dose of 500 mg followed by 14 doses of 250 mg every 6 hours) | 10 mg | ↑51% | ↑13% |
Table 10 shows the effect of dapagliflozin on other coadministered drugs. Dapagliflozin did not meaningfully affect the pharmacokinetics of the coadministered drugs.
Table 10: Effects of Dapagliflozin on the Systemic
Exposures of Coadministered Drugs
| Coadministered Drug (Dose Regimen) 1 | Dapagliflozin (Dose Regimen) 1 | Coadministered Drug | |
| Change2 in AUC3 | Change2 in Cmax | ||
| No dosing adjustments required for the following: | |||
| Oral Antidiabetic Agents | |||
| Metformin (1000 mg) | 20 mg | 0% | ↓5% |
| Pioglitazone (45 mg) | 50 mg | 0% | ↓7% |
| Sitagliptin (100 mg) | 20 mg | ↑1% | ↓11% |
| Glimepiride (4 mg) | 20 mg | ↑13% | ↑4% |
| Cardiovascular Agents | |||
| Hydrochlorothiazide (25 mg) | 50 mg | ↓1% | ↓5% |
| Bumetanide (1 mg) | 10 mg once daily for 7 days | ↑13% | ↑13% |
| Valsartan (320 mg) | 20 mg | ↑5% | ↓6% |
| Simvastatin (40 mg) | 20 mg | ↑19% | ↓6% |
| Digoxin (0.25 mg) | 20 mg loading dose then 10 mg once daily for 7 days | 0% | ↓1% |
| Warfarin (25 mg) S-warfarin R-warfarin | 20 mg loading dose then 10 mg once daily for 7 days | ↑3% | ↑7% |
| ↑6% | ↑8% | ||
| 1Single dose unless otherwise noted. 2Percent change (with/without coadministered drug and no change = 0%); ↑; and ↓ indicate the exposure increase and decrease, respectively. 3AUC = AUC(INF) for drugs given as single dose and AUC = AUC(TAU) for drugs given in multiple doses. |
|||
There have been no clinical efficacy studies conducted with XIGDUO XR combination tablets to characterize its effect on HbA1c reduction. XIGDUO XR is considered to be bioequivalent to coadministered dapagliflozin and metformin hydrochloride extended-release (XR) tablets [see CLINICAL PHARMACOLOGY]. Relative bioavailability studies between XIGDUO XR and coadministered dapagliflozin and metformin hydrochloride immediate-release (IR) tablets have not been conducted. The metformin hydrochloride XR tablets and metformin hydrochloride IR tablets have a similar extent of absorption (as measured by AUC), while peak plasma levels of XR tablets are approximately 20% lower than those of IR tablets at the same dose.
The coadministration of dapagliflozin and metformin XR tablets has been studied in treatment-naive patients inadequately controlled on diet and exercise alone. The coadministration of dapagliflozin and metformin IR or XR tablets has been studied in patients with type 2 diabetes inadequately controlled on metformin and compared with a sulfonylurea (glipizide) in combination with metformin. Treatment with dapagliflozin plus metformin at all doses produced clinically relevant and statistically significant improvements in HbA1c and fasting plasma glucose (FPG) compared to placebo in combination with metformin (initial or add-on therapy). HbA1c reductions were seen across subgroups including gender, age, race, duration of disease, and baseline BMI.
A total of 1241 treatment-naive patients with inadequately controlled type 2 diabetes (HbA1c ≥ 7.5% and ≤ 12%) participated in 2 active-controlled studies of 24-week duration to evaluate the safety and efficacy of initial therapy with dapagliflozin 5 mg or 10 mg in combination with metformin XR formulation.
In 1 study, 638 patients were randomized to 1 of 3 treatment arms following a 1-week lead-in period: dapagliflozin 10 mg plus metformin XR (up to 2000 mg/day), dapagliflozin 10 mg plus placebo, or metformin XR (up to 2000 mg/day) plus placebo. Metformin XR dose was up-titrated weekly in 500 mg increments, as tolerated, with a median dose achieved of 2000 mg.
The combination treatment of dapagliflozin 10 mg plus metformin XR provided statistically significant improvements in HbA1c and FPG compared with either of the monotherapy treatments and statistically significant reduction in body weight compared with metformin XR alone (see Table 11 and Figure 2). Dapagliflozin 10 mg as monotherapy also provided statistically significant improvements in FPG and statistically significant reduction in body weight compared with metformin alone and was noninferior to metformin XR monotherapy in lowering HbA1c.
Table 11: Results at Week 24 (LCOF1) in an
Active-Controlled Study of Dapagliflozin Initial Combination Therapy with
Metformin XR
| Efficacy Parameter | Dapagliflozin 10 mg + Metformin XR N=2112 |
Dapagliflozin 10 mg N=2192 |
Metformin XR N=2082 |
| HbA1c (%) | |||
| Baseline (mean) | 9.1 | 9.0 | 9.0 |
| Change from baseline (adjusted mean3) | -2.0 | -1.5 | -1.4 |
| Difference from dapagliflozin (adjusted mean3) (95% CI) | -0.54 (-0.7, -0.3) | ||
| Difference from metformin XR (adjusted mean3) (95% CI) | -0.54 (-0.8, -0.3) | 0.05 (-0.2, 0.2) | |
| Percent of patients achieving HbA1c < 7% adjusted for baseline | 46.6% | 31.7% | 35.2% |
| FPG (mg/dL) | |||
| Baseline (mean) | 189.6 | 197.5 | 189.9 |
| Change from baseline (adjusted mean3) | -60.4 | -46.4 | -34.8 |
| Difference from dapagliflozin (adjusted mean3) (95% CI) | -13.94 (-20.9, -7.0) | ||
| Difference from metformin XR (adjusted mean3) (95% CI) | -25.54 (-32.6, -18.5) | -11.66 (-18.6, -4.6) | |
| Body Weight (kg) | |||
| Baseline (mean) | 88.6 | 88.5 | 87.2 |
| Change from baseline (adjusted mean3) | -3.3 | -2.7 | -1.4 |
| Difference from metformin XR (adjusted mean3) (95% CI) | -2.04 (-2.6, -1.3) | -1.44 (-2.0, -0.7) | |
| 4LOCF: last observation (prior to rescue for
rescued patients) carried forward. 5All randomized patients who took at least one dose of double-blind study medication during the short-term double-blind period. 6Least squares mean adjusted for baseline value. 7p-value < 0.0001. 8Noninferior versus metformin XR. 9p-value < 0.05. |
|||
Figure 2: Adjusted Mean Change from Baseline Over Time
in HbA1c (%) in a 24-Week Active-Controlled Study of Dapagliflozin Initial
Combination Therapy with Metformin XR
 |
In the second study, 603 patients were randomized to 1 of 3 treatment arms following a 1-week lead-in period: dapagliflozin 5 mg plus metformin XR (up to 2000 mg/day), dapagliflozin 5 mg plus placebo, or metformin XR (up to 2000 mg/day) plus placebo. Metformin XR dose was up-titrated weekly in 500 mg increments, as tolerated, with a median dose achieved of 2000 mg.
The combination treatment of dapagliflozin 5 mg plus metformin XR provided statistically significant improvements in HbA1c and FPG compared with either of the monotherapy treatments and statistically significant reduction in body weight compared with metformin XR alone (see Table 12).
Table 12: Results at Week 24 (LOCF1) in an
Active-Controlled Study of Dapagliflozin Initial Combination Therapy with
Metformin XR
| Efficacy Parameter | Dapagliflozin 5 mg + Metformin XR N=1942 |
Dapagliflozin 5 mg N=2032 |
Metformin XR N=2012 |
| HbA1c (%) | |||
| Baseline (mean) | 9.2 | 9.1 | 9.1 |
| Change from baseline (adjusted mean3) | -2.1 | -1.2 | -1.4 |
| Difference from dapagliflozin (adjusted mean3) (95% CI) | -0.94 (-1.1, -0.6) | ||
| Difference from metformin XR (adjusted mean3) (95% CI) | -0.74 (-0.9, -0.5) | ||
| Percent of patients achieving HbA1c < 7% adjusted for baseline | 52.4%5 | 22.5% | 34.6% |
| FPG (mg/dL) | |||
| Baseline (mean) | 193.4 | 190.8 | 196.7 |
| Change from baseline (adjusted mean3) | -61.0 | -42.0 | -33.6 |
| Difference from dapagliflozin (adjusted mean3) (95% CI) | -19.14 (-26.7, -11.4) | ||
| Difference from metformin XR (adjusted mean3) (95% CI) | -27.54 (-35.1, -19.8) | ||
| Body Weight (kg) | |||
| Baseline (mean) | 84.2 | 86.2 | 85.8 |
| Change from baseline (adjusted mean3) | -2.7 | -2.6 | -1.3 |
| Difference from metformin XR (adjusted mean3) (95% CI) | -1.44 (-2.0, -0.7) | ||
| 10LOCF: last observation (prior to rescue for
rescued patients) carried forward. 11All randomized patients who took at least one dose of double-blind study medication during the short-term double-blind period. 12Least squares mean adjusted for baseline value. 13p-value < 0.0001. 14p-value < 0.05. |
|||
A total of 546 patients with type 2 diabetes with inadequate glycemic control (HbA1c ≥ 7% and ≤ 10%) participated in a 24-week, placebo-controlled study to evaluate dapagliflozin in combination with metformin. Patients on metformin at a dose of at least 1500 mg/day were randomized after completing a 2-week, single-blind, placebo lead-in period. Following the lead-in period, eligible patients were randomized to dapagliflozin 5 mg, dapagliflozin 10 mg, or placebo in addition to their current dose of metformin.
As add-on treatment to metformin, dapagliflozin 10 mg provided statistically significant improvements in HbA1c and FPG, and statistically significant reduction in body weight compared with placebo at Week 24 (see Table 13 and Figure 3). Statistically significant (p < 0.05 for both doses) mean changes from baseline in systolic blood pressure relative to placebo plus metformin were -4.5 mmHg and -5.3 mmHg with dapagliflozin 5 mg and 10 mg plus metformin, respectively.
Table 13: Results of a 24-Week (LOCF1)
Placebo-Controlled Study of Dapagliflozin in Add-On Combination with Metformin
| Efficacy Parameter | Dapagliflozin 10 mg+ Metformin N=1352 |
Dapagliflozin 5 mg+ Metformin N=1372 |
Placebo+ Metformin N=1372 |
| HbA1c (%) | |||
| Baseline (mean) | 7.9 | 8.2 | 8.1 |
| Change from baseline (adjusted mean3) | -0.8 | -0.7 | -0.3 |
| Difference from placebo (adjusted mean3) (95% CI) | -0.54 (-0.7, -0.3) | -0.44 (-0.6, -0.2) | |
| Percent of patients achieving HbA1c < 7% adjusted for baseline | 40.6%5 | 37.5%5 | 25.9% |
| FPG (mg/dL) | |||
| Baseline (mean) | 156.0 | 169.2 | 165.6 |
| Change from baseline at Week 24 (adjusted mean3) | -23.5 | -21.5 | -6.0 |
| Difference from placebo (adjusted mean3) (95% CI) | -17.54 (-25.0, -10.0) | -15.54 (-22.9, -8.1) | |
| Change from baseline at Week 1 (adjusted mean3) | -16.54 (N=115) | -12.04 (N=121) | 1.2 (N=126) |
| Body Weight (kg) | |||
| Baseline (mean) | 86.3 | 84.7 | 87.7 |
| Change from baseline (adjusted mean3) | -2.9 | -3.0 | -0.9 |
| Difference from placebo (adjusted mean3) (95% CI) | -2.04 (-2.6, -1.3) | -2.24 (-2.8, -1.5) | |
| 1LOCF: last observation (prior to rescue for
rescued patients) carried forward. 2All randomized patients who took at least one dose of double-blind study medication during the short-term double-blind period. 3Least squares mean adjusted for baseline value. 4p-value < 0.00001 versus placebo + metformin. 5p-value < 0.05 versus placebo + metformin. |
|||
Figure 3: Adjusted Mean
Change from Baseline Over Time in HbA1c (%) in a 24-Week Placebo-Controlled
Study of Dapagliflozin in Combination with Metformin
 |
A total of 816 patients with type 2 diabetes with inadequate glycemic control (HbA1c > 6.5% and ≤ 10%) were randomized in a 52-week, glipizide-controlled, noninferiority study to evaluate dapagliflozin as add-on therapy to metformin. Patients on metformin at a dose of at least 1500 mg/day were randomized following a 2-week placebo lead-in period to glipizide or dapagliflozin (5 or 2.5 mg, respectively) and were up-titrated over 18 weeks to optimal glycemic effect (FPG < 110 mg/dL, < 6.1 mmol/L) or to the highest dose level (up to glipizide 20 mg and dapagliflozin 10 mg) as tolerated by patients. Thereafter, doses were kept constant, except for down-titration to prevent hypoglycemia.
At the end of the titration period, 87% of patients treated with dapagliflozin had been titrated to the maximum study dose (10 mg) versus 73% treated with glipizide (20 mg). Dapagliflozin treatment led to a similar mean reduction in HbA1c from baseline at Week 52, compared with glipizide, thus demonstrating noninferiority (see Table 14). Dapagliflozin treatment led to a statistically significant mean reduction in body weight from baseline at Week 52 compared with a mean increase in body weight in the glipizide group. Statistically significant (p < 0.0001) mean change from baseline in systolic blood pressure relative to glipizide plus metformin was -5.0 mmHg with dapagliflozin plus metformin.
Table 14: Results at Week 52 (LOCF1) in an
Active-Controlled Study Comparing Dapagliflozin to Glipizide as Add-On to
Metformin
| Efficacy Parameter | Dapagliflozin + Metformin N=4002 |
Glipizide + Metformin N=4012 |
| HbA1c (%) | ||
| Baseline (mean) | 7.7 | 7.7 |
| Change from baseline (adjusted mean3) | -0.5 | -0.5 |
| Difference from glipizide + metformin (adjusted mean3) (95% CI) | 0.04 (-0.1, 0.1) | |
| Body Weight (kg) | ||
| Baseline (mean) | 88.4 | 87.6 |
| Change from baseline (adjusted mean3) | -3.2 | 1.4 |
| Difference from glipizide + metformin (adjusted mean3) (95% CI) | -4.75 (-5.1, -4.2) | |
| 1LOCF: last observation carried forward. 2Randomized and treated patients with baseline and at least 1 postbaseline efficacy measurement. 3Least squares mean adjusted for baseline value. 4Noninferior to glipizide + metformin. 5p-value < 0.0001. |
||
XIGDUO® XR
(ZIG-DO-OH X-R)
(dapagliflozin and metformin hcl) Extended-Release Tablets
What is the most important information I should know about XIGDUO XR?
XIGDUO XR can cause serious side effects, including:
Call your doctor right away if you have any of the following symptoms, which could be signs of lactic acidosis:
Most people who have had lactic acidosis with metformin have other things that, combined with the metformin use, led to the lactic acidosis. Tell your doctor if you have any of the following, because you have a higher chance for getting lactic acidosis with XIGDUO XR if you:
The best way to keep from having a problem with lactic acidosis from metformin is to tell your doctor if you have any of the problems in the list above. Your doctor may decide to stop your XIGDUO XR for a while if you have any of these things. XIGDUO XR can have other serious side effects. See “What are the possible side effects of XIGDUO XR?”
What is XIGDUO XR?
Who should not take XIGDUO XR?
Do not take XIGDUO XR if you:
What should I tell my healthcare provider before taking XIGDUO XR?
Before you take XIGDUO XR, tell your healthcare provider if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. XIGDUO XR may affect the way other medicines work and other medicines may affect the way XIGDUO XR works. Especially tell your healthcare provider if you take:
Ask your healthcare provider for a list of these medicines if you are not sure if your medicine is listed above.
Know the medicines you take. Keep a list of them and show it to you healthcare provider and pharmacist when you get a new medicine.
How should I take XIGDUO XR?
What should I avoid while taking XIGDUO XR?
What are the possible side effects of XIGDUO XR?
XIGDUO XR may cause serious side effects including:
See “What is the most important information I should know about XIGDUO XR?”
The most common side effects of XIGDUO XR include:
Tell your healthcare provider or pharmacist if you have any side effect that bothers you or does not go away.
These are not all of the possible side effects of XIGDUO XR. For more information, ask your healthcare provider or pharmacist.
Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
How should I store XIGDUO XR?
Store XIGDUO XR at room temperature between 68°F and 77°F (20°C and 25°C).
Keep XIGDUO XR and all medicines out of the reach of children.
General information about the safe and effective use of XIGDUO XR
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use XIGDUO XR for a condition for which it is not prescribed. Do not give XIGDUO XR to other people, even if they have the same symptoms you have. It may harm them.
This Medication Guide summarizes the most important information about XIGDUO XR. If you would like more information, talk to your healthcare provider. You can ask your pharmacist or healthcare provider for information about XIGDUO XR that is written for healthcare professionals.
For more information, go to www.xigduoxr.com or call 1-800-236-9933
What are the ingredients of XIGDUO XR?
Active ingredients: dapagliflozin and metformin hydrochloride
Inactive ingredients: microcrystalline cellulose, lactose anhydrous, crospovidone, silicon dioxide, magnesium stearate, carboxymethylcellulose sodium, and hypromellose 2208. The 5 mg/500 mg and 5 mg/1000 mg strength tablets of XIGDUO XR also contain hypromellose 2910.
The film coatings contain the following inactive ingredients: polyvinyl alcohol, titanium dioxide, polyethylene glycol, and talc. Additionally, the film coating for the XIGDUO XR 5 mg/500 mg tablets contains FD&C Yellow No. 6/Sunset Yellow FCF Aluminum Lake and the film coating for the XIGDUO XR 5 mg/1000 mg, 10 mg/500 mg, and 10 mg/1000 mg tablets contains iron oxides.
